Growth differentiation factor-15 as biomarker in uterine sarcomas

International Journal of Gynecological Cancer

Volumn 24, Issue 2, 2014, Pages 252-259

  Trovik, Jone ^a,b   Salvesen, Helga Birgitte ^a,b   Cuppens, Tine ^c   Amant, Frederic ^c,d   Staff, Anne Cathrine ^e,f  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d UNIVERSITY OF LEUVEN   (Belgium)

^e ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^f UNIVERSITY OF OSLO   (Norway)

Author keywords

Biomarker; Growth differentiation factor 15; Leiomyosarcoma; Uterine sarcoma

Indexed keywords

GROWTH DIFFERENTIATION FACTOR 15;

ADULT; ARTICLE; BLOOD SAMPLING; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SPECIFIC SURVIVAL; ENDOMETRIUM CANCER; FEMALE; HUMAN; IMMUNOASSAY; LEIOMYOSARCOMA; MAJOR CLINICAL STUDY; OVARY TUMOR; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; TUMOR DIAGNOSIS; UTERUS MYOMA; UTERUS SARCOMA;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; FEMALE; GROWTH DIFFERENTIATION FACTOR 15; HUMANS; LEIOMYOMA; MIDDLE AGED; SARCOMA; TUMOR MARKERS, BIOLOGICAL; UTERINE NEOPLASMS; YOUNG ADULT;

EID: 84893745195     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0000000000000037     Document Type: Article

References (30)

1. Amant F, Coosemans A, Debiec-Rychter M, et al. Clinical management of uterine sarcomas. Lancet Oncol. 2009;10:1188-1198.
2. Parker WH, Fu YS, Berek JS. Uterine sarcoma in patients operated on for presumed leiomyoma and rapidly growing leiomyoma. Obstet Gynecol. 1994;83:414-418.
3. Kawamura N, Ichimura T, Ito F, et al. Transcervical needle biopsy for the differential diagnosis between uterine sarcoma and leiomyoma. Cancer. 2002;94:1713-1720.
4. Leibsohn S, d'Ablaing G, Mishell DR Jr, et al. Leiomyosarcoma in a series of hysterectomies performed for presumed uterine leiomyomas. Am J Obstet Gynecol. 1990;162:968-974; discussion 74-6.
5. Park JY, Park SK, Kim DY, et al. The impact of tumor morcellation during surgery on the prognosis of patients with apparently early uterine leiomyosarcoma. Gynecol Oncol. 2011;122:255-259.
6. Perri T, Korach J, Sadetzki S, et al. Uterine leiomyosarcoma: does the primary surgical procedure matter? Int J Gynecol Cancer. 2009;19:257-260.
7. Van den Bosch T, Coosemans A, Morina M, et al. Screening for uterine tumours. Best Pract Res Clin Obstet Gynaecol. 2012;26:257-266.
8. Yilmaz N, Sahin I, Kilic S, et al. Assessment of the predictivity of preoperative serum CA 125 in the differential diagnosis of uterine leiomyoma and uterine sarcoma in the Turkish female population. Eur J Gynaecol Oncol. 2009;30:412-414.
9. Bauskin AR, Brown DA, Kuffner T, et al. Role of macrophage inhibitory cytokine-1 in tumorigenesis and diagnosis of cancer. Cancer Res. 2006;66:4983-4986.
10. Staff AC, Bock AJ, Becker C, et al. Growth differentiation factor-15 as a prognostic biomarker in ovarian cancer. Gynecol Oncol. 2010;118:237-243.
11. Staff AC, Trovik J, Eriksson AG, et al. Elevated plasma growth differentiation factor-15 correlates with lymph node metastases and poor survival in endometrial cancer. Clin Cancer Res. 2011;17:4825-4833.
12. Prat J. FIGO staging for uterine sarcomas. Int J Gynaecol Obstet. 2009;104:177-178.
13. Odegaard E, Davidson B, Elgaaen BV, et al. Circulating calprotectin in ovarian carcinomas and borderline tumors of the ovary. Am J Obstet Gynecol. 2008;198:e1-e7.
14. Kempf T, Horn-Wichmann R, Brabant G, et al. Circulating concentrations of growth-differentiation factor 15 in apparently healthy elderly individuals and patients with chronic heart failure as assessed by a new immunoradiometric sandwich assay. Clin Chem. 2007;53:284-291.
15. Trovik J. Endometrial Carcinoma; Can Biomarkers Aid in the Prediction of Aggressive Disease? Bergen, Norway: University of Bergen, Norway; 2012. ISBN: 978-82-308-2019-3.
16. Wiklund FE, Bennet AM, Magnusson PK, et al. Macrophage inhibitory cytokine-1 (MIC-1/GDF15): a new marker of all-cause mortality. Aging Cell. 2010;9:1057-1064.
17. Brown DA, Breit SN, Buring J, et al. Concentration in plasma of macrophage inhibitory cytokine-1 and risk of cardiovascular events in women: a nested case-control study. Lancet. 2002;359:2159-2163.
18. Lawton LN, Bonaldo MF, Jelenc PC, et al. Identification of a novel member of the TGF-beta superfamily highly expressed in human placenta. Gene. 1997;203:17-26.
19. Sugulle M, Dechend R, Herse F, et al. Circulating and placental growth-differentiation factor 15 in preeclampsia and in pregnancy complicated by diabetes mellitus. Hypertension. 2009;54:106-112.
20. Bootcov MR, Bauskin AR, Valenzuela SM, et al. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc Natl Acad Sci U S A. 1997;94:11514-11519.
21. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-674.
22. Kim HS, Han KH, Chung HH, et al. Neutrophil to lymphocyte ratio for preoperative diagnosis of uterine sarcomas: a case-matched comparison. Eur J Surg Oncol. 2010;36:691-698.
23. Zimmers TA, Jin X, Hsiao EC, et al. Growth differentiation factor-15/macrophage inhibitory cytokine-1 induction after kidney and lung injury. Shock. 2005;23:543-548.
24. Brown DA, Stephan C, Ward RL, et al. Measurement of serum levels of macrophage inhibitory cytokine 1 combined with prostate-specific antigen improves prostate cancer diagnosis. Clin Cancer Res. 2006;12:89-96.
25. Koopmann J, Buckhaults P, Brown DA, et al. Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers. Clin Cancer Res. 2004;10: 2386-2392.
26. Agarwal MK, Hastak K, Jackson MW, et al. Macrophage inhibitory cytokine 1 mediates a p53-dependent protective arrest in S phase in response to starvation for DNA precursors. Proc Natl Acad Sci U S A. 2006;103:16278-16283.
27. Juang CM, Yen MS, Horng HC, et al. Potential role of preoperative serum CA125 for the differential diagnosis between uterine leiomyoma and uterine leiomyosarcoma. Eur J Gynaecol Oncol. 2006;27:370-374.
28. Goto A, Takeuchi S, Sugimura K, et al. Usefulness of Gd-DTPA contrast-enhanced dynamic MRI and serum determination of LDH and its isozymes in the differential diagnosis of leiomyosarcoma from degenerated leiomyoma of the uterus. Int J Gynecol Cancer. 2002;12:354-361.
29. Nagamatsu A, Umesaki N, Li L, et al. Use of 18F-fluorodeoxyglucose positron emission tomography for diagnosis of uterine sarcomas. Oncol Rep. 2010;23:1069-1076.
30. Abeler VM, Royne O, Thoresen S, et al. Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients. Histopathology. 2009;54:355-364.